Johnson & Johnson is trading an undisclosed sum for private drugmaker Novira Therapeutics, picking up an early-stage treatment for hepatitis B and a handful of antivirals.
Japanese drugmaker Eisai has aligned itself with France's Paoli Calmettes Institute to spotlight potential oncology therapies.
Partners Merck KGaA and Pfizer are looking to prove their 5th-place immuno-oncology treatment can contend with the leaders in the field, launching a late-stage lung cancer study to establish the antibody's promise.
F-star has become the latest biotech to bag itself a Big Pharma exec. Neil Brewis is now heading up scientific operations at the immuno-oncology player, having previously served as GlaxoSmithKline's head of biopharmaceutical research.
A consortium of top-tier European research centers has snagged €23 million ($25 million) to take a HIV vaccine toward the clinic. The Imperial College London-led project is drawing on the scientific capabilities of 23 research centers in an attempt to move a HIV vaccine into Phase I within the next 5 years.
European biotechs raised more than €1 billion ($1.1 billion) through IPOs in their home markets and overseas in the first 9 months of 2015, according to market analyst Biocom. But while the total represents an 18% increase over the same period of last year, a stuttering final quarter could cause 2015 to end with a whimper.
Allergan expanded its pipeline with a $50 million deal to bring in a late-stage treatment for dry eye as the company works to reaffirm its commitment to R&D in the face of industrywide scrutiny.
Vertex is ready to get its checkbook out to quell talk of it being a takeover target for Biogen and Gilead. The plan is to use the cash flow from recently approved cystic fibrosis drug Orkambi to strike pipeline-broadening deals, with gene therapy and RNA two fields in the company's sights.
Biogen is in the midst of a wide-ranging reorganization that will send more than 800 employees out the door, but the company isn't backing away from its penchant for high-risk R&D, pressing forward with a pipeline focused on first-in-class therapies.
Flagship Ventures, the group behind microbiome success story Seres Therapeutics, is delving further into gut science with a new startup that aims to treat cancer by harnessing the power of the body's many bacterial tenants.
GlaxoSmithKline and partner Isis Pharmaceuticals are plotting a pivotal trial in the rare TTR amyloid cardiomyopathy, an inherited disease that impairs the heart muscle.
Boston biotech Wave Life Sciences and Australian regenerative medicine developer Mesoblast are the latest companies crowding into the ever-tightening IPO window for drugmakers, filing to make Nasdaq debuts amid diminishing returns for like-minded upstarts.
A new semimonthly treatment from Johnson & Johnson and ViiV Healthcare tamped down HIV as well as daily therapy in a midstage trial, promising a more convenient option for patients.
GlaxoSmithKline has struck a deal to trial its anti-OX40 monoclonal antibody in combination with Merck's Keytruda. The Phase I study is part of a slate of programs that GSK is hoping will support filings for up to 20 new drug approvals in the coming years, the success rate of which will go a long way to deciding whether the company can bounce back from its recent travails.
Sanofi is pairing up with Germany's BioNTech in a collaboration potentially worth $1.5 billion, licensing some early-stage cancer immunotherapies that use messenger RNA to target tumors.
The Bill & Melinda Gates Foundation joined German billionaire Dietmar Hopp in a venture syndicate that is injecting a whopping $110 million of fresh funds into CureVac, a German mRNA biotech which has now garnered some $330 million in support.
Boehringer Ingelheim has expanded its crowdsourced R&D program into the field of psychiatric diseases, broadening its partnership with Germany's BioMed X to spotlight new therapies.
Bristol-Myers Squibb is acquiring private biotech Cardioxyl Pharmaceuticals in a deal that could be worth more than $2 billion, bringing in a Phase II treatment for heart failure.
Shire signed a deal to buy Dyax for $5.9 billion, planning to snatch up a smaller competitor and fortify its rare disease business without taking its eyes off of acquisition target Baxalta.
Merck KGaA has teamed up with Selvita to discover small molecule drugs against multiple oncology indications. The alliance builds on an earlier two-year research collaboration into the discovery of enzyme inhibitors to regulate metabolic processes in cancer cells.